Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Jennifer Cantley(Arvinas (United States)), Robert L. Yauch(Gene Therapy Laboratory)
Cited by 125
Related Papers
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
|Nature Communications|2025|11
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
|Research Square|2022|2